Mirikizumab sustains multidomain UC remission through four years

Provides the first long-term extension data pairing durable endoscopic and histologic remission with corticosteroid-sparing and bowel-urgency outcomes for an anti-IL-23 p19 agent in ulcerative colitis.

mirikizumabinterleukin-23 p19 inhibitorulcerative colitisbiologic maintenancecorticosteroid-sparingopen-label extensionLUCENT-3endoscopic remissionhistologic remission Gastroenterology / Hepatology

Background Information

Four-year study shows lasting ulcerative colitis remission with mirikizumab.

Sustained long-term treatment is crucial for managing chronic conditions like ulcerative colitis. Mirikizumab maintained remission in high percentages, with 77.7% clinical remission at 212 weeks. This study supports mirikizumab’s long-term efficacy and safety, vital for patients with previous biologic failure. Mirikizumab offers durable control in ulcerative colitis over four years.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sands BE, Clemow DB, D'Haens G, Irving PM, Kobayashi T, Peyrin-Biroulet L, Samaan K, Gaur A, Arora R, Todd K, Moses R, Dignass A

Citation: Sands BE, Clemow DB, D'Haens G, et al. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study. Inflammatory bowel diseases. 2026;32(6):1023-1040. doi:10.1093/ibd/izag007

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →